Pharvaris/$PHVS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pharvaris
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
- Ticker
- $PHVS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 148
- Headquarters
- Zug, Switzerland
- Website
- pharvaris.com
Pharvaris Metrics
BasicAdvanced
$2.4B
-
-$2.92
-2.33
-
Price and volume
Market cap
$2.4B
Beta
-2.33
52-week high
$43.25
52-week low
$21.02
Average daily volume
657K
Financial strength
Current ratio
11.941
Quick ratio
11.819
Long term debt to equity
0.002
Total debt to equity
0.002
Interest coverage (TTM)
-1,054.74%
Profitability
EBITDA (TTM)
-202.997
Effective tax rate (TTM)
-1.40%
Management effectiveness
Return on assets (TTM)
-42.32%
Return on equity (TTM)
-70.46%
Valuation
Price to book
8.03
Price to tangible book (TTM)
8.03
Price to free cash flow (TTM)
-12.96
Free cash flow yield (TTM)
-7.72%
Free cash flow per share (TTM)
-2.654
Growth
Earnings per share change (TTM)
-15.29%
3-year earnings per share growth (CAGR)
-1.14%
What the Analysts think about Pharvaris
Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.
Analyst projections of the future price of Pharvaris stock.
Bulls say / Bears say
In CHAPTER-3, once-daily deucrictibant XR cut monthly HAE attacks by 83% versus placebo over 24 weeks, with all secondary endpoints met and no treatment-related serious adverse events reported. This offers a strong clinical basis for a potential oral prevention option. (Pharvaris)
In the Phase 3 RAPIDe-3 trial, oral deucrictibant brought symptom relief in a median 1.28 hours, versus more than 12 hours with placebo, and no treatment-related serious or severe adverse events were reported. The results support a potential oral option for treating attacks. (The Lancet)
The immediate-release treatment is under formal review by both the FDA and EMA, with the FDA decision targeted for April 2027. If approved, this could bring a first product closer to market while the company advances its prevention tablet. (SEC)
Deucrictibant would enter a competitive HAE market that already includes injectable prevention treatments and the oral drug Orladeyo. Newer therapies have also recently reached the market, which could make it harder to win patients and payer coverage. (Clinical Trials Arena)
Two CHAPTER-3 participants had Grade 2 liver-enzyme elevations, although Pharvaris cited possible confounding factors and said neither had symptoms or raised bilirubin. Longer-term safety data are still needed to clarify whether this will affect monitoring or uptake. (Investing.com)
Pharvaris remains pre-revenue and reported a €47.8 million net loss in the second quarter. It says its cash should fund operations into 2028, but it has relied on share offerings and says it may need further capital, leaving investors exposed to possible dilution. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.
Pharvaris Financial Performance
Revenues and expenses
Pharvaris Earnings Performance
Company profitability
Upcoming events
No upcoming events
Pharvaris News
AllArticlesVideos
Funds containing Pharvaris
Fund name | Fund size | $PHVS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.15% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.15% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.05% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.05% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.